| Cover | 12 Months Ended |
| Dec. 31, 2022 | |
| Cover [Abstract] | |
| Document Type | DEF 14A |
| Entity Registrant Name | Bio-Rad Laboratories, Inc. |
| Entity Central Index Key | 0000012208 |
| Amendment Flag | false |
| Pay vs Performance Disclosure | 12 Months Ended | |||
| Dec. 31, 2022 USD ($) | Dec. 31, 2021 USD ($) | Dec. 31, 2020 USD ($) | ||
| Pay vs Performance Disclosure [Table] | ||||
| Pay vs Performance [Table Text Block] | PAY VERSUS PERFORMANCE TABLE The following table sets forth information concerning the compensation of our NEOs for each of the fiscal years ended December 31, 2020, 2021 and 2022, and our financial performance for each such fiscal year: (a) (b) (c) (d) (e) (f) (g) (h) (i) Value of Initial Fixed Year Summary Compensation ( 1) Average Average (1) Total Peer Group (2) Net Income Operating (3) 2022 7,527,985 (8,179,992) 2,613,905 (201,923) 113.64 142.26 (3,627,535,000) 482,616,000 2021 8,695,925 20,595,138 3,192,227 4,907,168 204.19 184.53 4,254,257,000 500,336,000 2020 7,992,423 21,512,399 2,825,690 4,701,780 157.54 133.01 3,814,229,000 421,326,000 (1) Amounts represent compensation actually paid to our PEO and the average compensation actually paid to our remaining NEOs for the relevant fiscal year, as determined under SEC rules (and described below), which includes the individuals indicated in the table below for each fiscal year: Year PEO Non-PEO NEOs 2022 Norman Schwartz I lan Daskal Andrew J. Last Dara Grantham Wright Simon May 2021 Norman Schwartz Ilan Daskal, Andrew J. Last Dara Grantham Wright Michael Crowley 2020 Norman Schwartz I lan Daskal Andrew J. Last, Dara Grantham Wright Annette Tumolo Compensation actually paid to our NEOs represents the “Total” compensation reported in the Summary Compensation Table for the applicable fiscal year, as adjusted as follows: 2020 2021 2022 Adjustments PEO Average PEO Average PEO Average Deduction for Amounts Reported under the “Stock Awards” and “Option Awards” Columns in the Summary Compensation Table for Applicable FY (4,979,219) (1,552,522) (5,550,383) (2,000,631) (5,398,348) (1,687,288) Increase based on ASC 718 Fair Value of Awards Granted during Applicable FY that Remain Unvested as of Applicable FY End, determined as of Applicable FY End 5,810,738 1,777,727 5,069,873 1,910,628 3,112,887 1,702,143 Increase/deduction for Awards Granted during Prior FY that were Outstanding and Unvested as of Applicable FY End, determined based on change in ASC 718 Fair Value from Prior FY End to Applicable FY End 9,722,027 1,422,262 6,739,338 1,214,409 (8,215,022) (2,062,446) Increase/deduction for Awards Granted during Prior FY that Vested During Applicable FY, determined based on change in ASC 718 Fair Value from Prior FY End to Vesting Date 2,966,430 228,623 5,640,385 590,535 (5,207,494) (768,237) TOTAL ADJUSTMENTS 13,519,976 1,876,090 11,899,213 1,714,941 (15,707,977) (2,815,828) Fair value or change in fair value, as applicable, of equity awards in the “Compensation Actually Paid” columns was determined by reference to (i) for RSU awards, the closing price per share on the applicable year-end date(s) or, in the case of vesting dates, the closing price per share on the applicable vesting date(s); (ii) for PSU awards, the same valuation methodology as RSU awards above except that the year-end values are multiplied by the probability of achievement of the applicable performance objective as of the applicable date; and (iii) for stock options, a Black Scholes value as of the applicable year-end or vesting date(s), determined based on the same methodology as used to determine grant date fair value but using the closing stock price on the applicable revaluation date as the current market price and an expected life set equal to the remaining life of the award in the case of underwater stock options and, in the case of in-the-money options, the expected life estimated at the grant date reduced by the time lapsed from the grant date to the revaluation date, and in all cases based on volatility and risk free rates determined as of the revaluation date based on the expected life period and based on an expected dividend rate of 0%. For additional information on the assumptions used to calculate the valuation of the awards, see the Notes to Consolidated Financial Statements in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022 and prior fiscal years. (2) For the relevant fiscal year, represents the cumulative TSR (the “Peer Group TSR”) of the S&P 500 Life Sciences Tools & Services Index (the “Peer Group”). (3) Operating Income is a GAAP measure. We selected operating income as the Company Selected Measure because, among other things, operating income is a significantly weighted measure under our cash based-incentive bonus plan. | |||
| Named Executive Officers, Footnote [Text Block] | (1) Amounts represent compensation actually paid to our PEO and the average compensation actually paid to our remaining NEOs for the relevant fiscal year, as determined under SEC rules (and described below), which includes the individuals indicated in the table below for each fiscal year: Year PEO Non-PEO NEOs 2022 Norman Schwartz I lan Daskal Andrew J. Last Dara Grantham Wright Simon May 2021 Norman Schwartz Ilan Daskal, Andrew J. Last Dara Grantham Wright Michael Crowley 2020 Norman Schwartz I lan Daskal Andrew J. Last, Dara Grantham Wright Annette Tumolo | |||
| Peer Group Issuers, Footnote [Text Block] | For the relevant fiscal year, represents the cumulative TSR (the “Peer Group TSR”) of the S&P 500 Life Sciences Tools & Services Index (the “Peer Group”). | |||
| PEO Total Compensation Amount | $ 7,527,985 | $ 8,695,925 | $ 7,992,423 | |
| PEO Actually Paid Compensation Amount | $ (8,179,992) | 20,595,138 | 21,512,399 | |
| Adjustment To PEO Compensation, Footnote [Text Block] | Compensation actually paid to our NEOs represents the “Total” compensation reported in the Summary Compensation Table for the applicable fiscal year, as adjusted as follows: 2020 2021 2022 Adjustments PEO Average PEO Average PEO Average Deduction for Amounts Reported under the “Stock Awards” and “Option Awards” Columns in the Summary Compensation Table for Applicable FY (4,979,219) (1,552,522) (5,550,383) (2,000,631) (5,398,348) (1,687,288) Increase based on ASC 718 Fair Value of Awards Granted during Applicable FY that Remain Unvested as of Applicable FY End, determined as of Applicable FY End 5,810,738 1,777,727 5,069,873 1,910,628 3,112,887 1,702,143 Increase/deduction for Awards Granted during Prior FY that were Outstanding and Unvested as of Applicable FY End, determined based on change in ASC 718 Fair Value from Prior FY End to Applicable FY End 9,722,027 1,422,262 6,739,338 1,214,409 (8,215,022) (2,062,446) Increase/deduction for Awards Granted during Prior FY that Vested During Applicable FY, determined based on change in ASC 718 Fair Value from Prior FY End to Vesting Date 2,966,430 228,623 5,640,385 590,535 (5,207,494) (768,237) TOTAL ADJUSTMENTS 13,519,976 1,876,090 11,899,213 1,714,941 (15,707,977) (2,815,828) Fair value or change in fair value, as applicable, of equity awards in the “Compensation Actually Paid” columns was determined by reference to (i) for RSU awards, the closing price per share on the applicable year-end date(s) or, in the case of vesting dates, the closing price per share on the applicable vesting date(s); (ii) for PSU awards, the same valuation methodology as RSU awards above except that the year-end values are multiplied by the probability of achievement of the applicable performance objective as of the applicable date; and (iii) for stock options, a Black Scholes value as of the applicable year-end or vesting date(s), determined based on the same methodology as used to determine grant date fair value but using the closing stock price on the applicable revaluation date as the current market price and an expected life set equal to the remaining life of the award in the case of underwater stock options and, in the case of in-the-money options, the expected life estimated at the grant date reduced by the time lapsed from the grant date to the revaluation date, and in all cases based on volatility and risk free rates determined as of the revaluation date based on the expected life period and based on an expected dividend rate of 0%. For additional information on the assumptions used to calculate the valuation of the awards, see the Notes to Consolidated Financial Statements in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022 and prior fiscal years. (2) For the relevant fiscal year, represents the cumulative TSR (the “Peer Group TSR”) of the S&P 500 Life Sciences Tools & Services Index (the “Peer Group”). (3) Operating Income is a GAAP measure. We selected operating income as the Company Selected Measure because, among other things, operating income is a significantly weighted measure under our cash based-incentive bonus plan. | |||
| Non-PEO NEO Average Total Compensation Amount | $ 2,613,905 | 3,192,227 | 2,825,690 | |
| Non-PEO NEO Average Compensation Actually Paid Amount | $ (201,923) | 4,907,168 | 4,701,780 | |
| Adjustment to Non-PEO NEO Compensation Footnote [Text Block] | Compensation actually paid to our NEOs represents the “Total” compensation reported in the Summary Compensation Table for the applicable fiscal year, as adjusted as follows: 2020 2021 2022 Adjustments PEO Average PEO Average PEO Average Deduction for Amounts Reported under the “Stock Awards” and “Option Awards” Columns in the Summary Compensation Table for Applicable FY (4,979,219) (1,552,522) (5,550,383) (2,000,631) (5,398,348) (1,687,288) Increase based on ASC 718 Fair Value of Awards Granted during Applicable FY that Remain Unvested as of Applicable FY End, determined as of Applicable FY End 5,810,738 1,777,727 5,069,873 1,910,628 3,112,887 1,702,143 Increase/deduction for Awards Granted during Prior FY that were Outstanding and Unvested as of Applicable FY End, determined based on change in ASC 718 Fair Value from Prior FY End to Applicable FY End 9,722,027 1,422,262 6,739,338 1,214,409 (8,215,022) (2,062,446) Increase/deduction for Awards Granted during Prior FY that Vested During Applicable FY, determined based on change in ASC 718 Fair Value from Prior FY End to Vesting Date 2,966,430 228,623 5,640,385 590,535 (5,207,494) (768,237) TOTAL ADJUSTMENTS 13,519,976 1,876,090 11,899,213 1,714,941 (15,707,977) (2,815,828) Fair value or change in fair value, as applicable, of equity awards in the “Compensation Actually Paid” columns was determined by reference to (i) for RSU awards, the closing price per share on the applicable year-end date(s) or, in the case of vesting dates, the closing price per share on the applicable vesting date(s); (ii) for PSU awards, the same valuation methodology as RSU awards above except that the year-end values are multiplied by the probability of achievement of the applicable performance objective as of the applicable date; and (iii) for stock options, a Black Scholes value as of the applicable year-end or vesting date(s), determined based on the same methodology as used to determine grant date fair value but using the closing stock price on the applicable revaluation date as the current market price and an expected life set equal to the remaining life of the award in the case of underwater stock options and, in the case of in-the-money options, the expected life estimated at the grant date reduced by the time lapsed from the grant date to the revaluation date, and in all cases based on volatility and risk free rates determined as of the revaluation date based on the expected life period and based on an expected dividend rate of 0%. For additional information on the assumptions used to calculate the valuation of the awards, see the Notes to Consolidated Financial Statements in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022 and prior fiscal years. (2) For the relevant fiscal year, represents the cumulative TSR (the “Peer Group TSR”) of the S&P 500 Life Sciences Tools & Services Index (the “Peer Group”). (3) Operating Income is a GAAP measure. We selected operating income as the Company Selected Measure because, among other things, operating income is a significantly weighted measure under our cash based-incentive bonus plan. | |||
| Compensation Actually Paid vs. Total Shareholder Return [Text Block] | TSR amounts reported in the graph assume an initial fixed investment of $100, and that all dividends, if any, were reinvested. | |||
| Compensation Actually Paid vs. Net Income [Text Block] | ||||
| Compensation Actually Paid vs. Company Selected Measure [Text Block] | ||||
| Tabular List [Table Text Block] | Pay Versus Performance Tabular List We believe the following performance measures represent the most important financial performance measures used by us to link compensation actually paid to our NEOs for the fiscal year ended December 31, 2022: • Operating Income • Sales • Adjusted EBITDA Margin. For additional details regarding our most important financial performance measures, please see the sections titled “Incentive Bonus Plan, Or IBP (Cash-Based Incentive Program)” and “Equity Compensation” in our Compensation Discussion and Analysis (CD&A) elsewhere in this Proxy Statement. | |||
| Total Shareholder Return Amount | $ 113.64 | 204.19 | 157.54 | |
| Peer Group Total Shareholder Return Amount | [1] | 142.26 | 184.53 | 133.01 |
| Net Income (Loss) | $ (3,627,535,000,000) | $ 4,254,257,000,000 | $ 3,814,229,000,000 | |
| Company Selected Measure Amount | 482,616 | 500,336 | 421,326 | |
| PEO Name | Norman Schwartz | Norman Schwartz | ||
| Measure [Axis]: 1 | ||||
| Pay vs Performance Disclosure [Table] | ||||
| Measure Name | Operating Income | |||
| Measure [Axis]: 2 | ||||
| Pay vs Performance Disclosure [Table] | ||||
| Measure Name | Sales | |||
| Measure [Axis]: 3 | ||||
| Pay vs Performance Disclosure [Table] | ||||
| Measure Name | Adjusted EBITDA Margin. | |||
| Non-PEO NEO [Member] | ||||
| Pay vs Performance Disclosure [Table] | ||||
| Adjustment to Compensation Amount | $ (1,687,288) | $ (2,000,631) | $ (1,552,522) | |
| Non-PEO NEO [Member] | Adjustment Type 2 [Member] | ||||
| Pay vs Performance Disclosure [Table] | ||||
| Adjustment to Compensation Amount | 1,702,143 | 1,910,628 | 1,777,727 | |
| Non-PEO NEO [Member] | Adjustment Type 3 [Member] | ||||
| Pay vs Performance Disclosure [Table] | ||||
| Adjustment to Compensation Amount | (2,062,446) | 1,214,409 | 1,422,262 | |
| Non-PEO NEO [Member] | Adjustment Type 4 [Member] | ||||
| Pay vs Performance Disclosure [Table] | ||||
| Adjustment to Compensation Amount | $ (768,237) | $ 590,535 | $ 228,623 | |
| Non-PEO NEO [Member] | Llan Daskal [Member] | ||||
| Pay vs Performance Disclosure [Table] | ||||
| PEO Name | lan Daskal | Ilan Daskal, | lan Daskal | |
| Non-PEO NEO [Member] | Andrew J Last [Member] | ||||
| Pay vs Performance Disclosure [Table] | ||||
| PEO Name | Andrew J. Last | Andrew J. Last, | ||
| Non-PEO NEO [Member] | Dara Grantham Wright [Member] | ||||
| Pay vs Performance Disclosure [Table] | ||||
| PEO Name | Dara Grantham Wright | Dara Grantham Wright | Dara Grantham Wright | |
| Non-PEO NEO [Member] | Simon May [Member] | ||||
| Pay vs Performance Disclosure [Table] | ||||
| PEO Name | Simon May | |||
| Non-PEO NEO [Member] | Michael Crowley [Member] | ||||
| Pay vs Performance Disclosure [Table] | ||||
| PEO Name | Michael Crowley | |||
| Non-PEO NEO [Member] | Annette Tumolo [Member] | ||||
| Pay vs Performance Disclosure [Table] | ||||
| PEO Name | Annette Tumolo | |||
| PEO [Member] | ||||
| Pay vs Performance Disclosure [Table] | ||||
| Adjustment to Compensation Amount | $ (5,398,348) | $ (5,550,383) | $ (4,979,219) | |
| PEO [Member] | Adjustment Type 2 [Member] | ||||
| Pay vs Performance Disclosure [Table] | ||||
| Adjustment to Compensation Amount | 3,112,887 | 5,069,873 | 5,810,738 | |
| PEO [Member] | Adjustment Type 3 [Member] | ||||
| Pay vs Performance Disclosure [Table] | ||||
| Adjustment to Compensation Amount | (8,215,022) | 6,739,338 | 9,722,027 | |
| PEO [Member] | Adjustment Type 4 [Member] | ||||
| Pay vs Performance Disclosure [Table] | ||||
| Adjustment to Compensation Amount | $ (5,207,494) | $ 5,640,385 | $ 2,966,430 | |
| [1]Operating Income is a GAAP measure. We selected operating income as the Company Selected Measure because, among other things, operating income is a significantly weighted measure under our cash based-incentive bonus plan. | ||||
